alendronate has been researched along with 6-amino-1-hydroxyhexane-1,1-diphosphonate in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, BN; Caldera, A; Croft, SL; Docampo, R; Grimley, JS; Heath, HT; Kendrick, H; Lewis, JC; Lira, R; Martin, MB; Moreno, SN; Oldfield, E; Urbina, JA; Yardley, V | 1 |
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Bachmann, R; Bisping, M; Born, AR; Cortesi, R; Glatt, M; Green, JR; Guiglia, G; Jaeggi, KA; Jeker, H; Klein, R; Müller, K; Ramseier, U; Schmid, J; Schreiber, G; Seltenmeyer, Y; Widler, L | 1 |
| Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM | 1 |
| Bruchhaus, I; Chan, JM; Croft, SL; Flessner, RM; Ghosh, S; Kemp, RG; Kendrick, H; Kobayashi, S; Lea, CR; Lewis, JC; Loftus, TC; Meints, GA; Nozaki, T; Oldfield, E; Tovian, ZS | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Aloisi, R; Benetti, D; Fantozzi, R; Mian, M; Rosini, S | 1 |
| Adami, S; Braga, V; Fracassi, E; Gatti, D; Gerardi, D; Guidi, G | 1 |
| Chandia, M; Costa, MC; Costa, MR; Fausto, R; Gano, L; Neves, M; Pereira, N; Rosado, M | 1 |
| Byard, S; Duer, MJ; Ironside, MS; Reid, DG | 1 |
| Hyvönen, H; Kolehmainen, E; Lahtinen, M; Peräniemi, S; Saari, AL; Turhanen, P; Vepsäläinen, J; Ylisirniö, M | 1 |
| Bhardwaj, A; Osunkwo, I; Sinha, NK; Swe, KM | 1 |
| Casasnovas, R; Fernández, D; Frau, J; Ortega-Castro, J; Ramis, R; Vilanova, B | 1 |
| Bhardwaj, A; Sinha, NK; Swe, KMM | 1 |
2 review(s) available for alendronate and 6-amino-1-hydroxyhexane-1,1-diphosphonate
| Article | Year |
|---|---|
Treatment for osteoporosis in people with ß-thalassaemia.
Topics: Adolescent; Adult; Alendronate; beta-Thalassemia; Bone Density; Bone Density Conservation Agents; Child; Clodronic Acid; Diphosphonates; Female; Femur Neck; Humans; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Zinc Sulfate | 2016 |
Treatment for osteoporosis in people with beta-thalassaemia.
Topics: Adult; Alendronate; beta-Thalassemia; Child; Clodronic Acid; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Pamidronate | 2023 |
1 trial(s) available for alendronate and 6-amino-1-hydroxyhexane-1,1-diphosphonate
| Article | Year |
|---|---|
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.
Topics: Alendronate; Alkaline Phosphatase; Amino Acids; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diphosphonates; Female; Humans; Infusions, Intravenous; Isoenzymes; Osteoporosis, Postmenopausal; Pamidronate; Structure-Activity Relationship; Triglycerides | 2000 |
14 other study(ies) available for alendronate and 6-amino-1-hydroxyhexane-1,1-diphosphonate
| Article | Year |
|---|---|
Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy.
Topics: Animals; Antiprotozoal Agents; Chlorocebus aethiops; Diphosphonates; Leishmania donovani; Plasmodium falciparum; Structure-Activity Relationship; Toxoplasma; Trypanosoma brucei brucei; Trypanosoma cruzi; Vero Cells | 2001 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Topics: Animals; Bone Resorption; Calcitriol; Diphosphonates; Hypercalcemia; Imidazoles; In Vitro Techniques; Kidney; Mice; Pamidronate; Parathyroidectomy; Rats; Skull; Structure-Activity Relationship; Thyroidectomy; Zoledronic Acid | 2002 |
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid | 2003 |
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo.
Topics: Animals; Antimalarials; Antiprotozoal Agents; Cell Line; Cricetinae; Diphosphonates; Entamoeba histolytica; Entamoebiasis; Humans; In Vitro Techniques; Liver Abscess; Malaria; Mice; Mice, Inbred BALB C; Plasmodium berghei; Plasmodium falciparum; Structure-Activity Relationship | 2004 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Effects of bisphosphonate derivatives on macrophage function.
Topics: Alendronate; Animals; Bone Diseases; Clodronic Acid; Diphosphonates; Glucuronidase; Lysosomes; Macrophages, Peritoneal; Phagocytosis; Rats; Superoxides | 1994 |
Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies.
Topics: Alendronate; Animals; Bone and Bones; Diphosphonates; Durapatite; Energy Transfer; Female; Mice; Models, Molecular; Molecular Conformation; Pamidronate; Radiochemistry; Radioisotopes; Radiopharmaceuticals; Samarium; Tissue Distribution | 2002 |
Bisphosphonate protonation states, conformations, and dynamics on bone mineral probed by solid-state NMR without isotope enrichment.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Crystallization; Diphosphonates; Horses; Imidazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Pamidronate; Structure-Activity Relationship; Technology, Pharmaceutical; Zoledronic Acid | 2010 |
Systematic study of the physicochemical properties of a homologous series of aminobisphosphonates.
Topics: Alendronate; Diphosphonates; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Solubility; Temperature; Water | 2012 |
New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.
Topics: Alendronate; Binding Sites; Bone Density Conservation Agents; Diphosphonates; Drug Discovery; Geranyltranstransferase; Hemiterpenes; Humans; Molecular Dynamics Simulation; Organophosphorus Compounds; Pamidronate; Protein Binding; Structure-Activity Relationship; Thermodynamics | 2017 |